Ducho Christian, Balzarini Jan, Naesens Lieve, De Clercq Erik, Meier Chris
Institut für Organische Chemie, Universität Hamburg, Germany.
Antivir Chem Chemother. 2002 Mar;13(2):129-41. doi: 10.1177/095632020201300206.
The synthesis of phenyl-substituted and benzoannulated cycloSal phosphate triesters of the nucleoside analogue 2',3'-dideoxy-2',3'-didehydrothymidine (d4T, Zerit) as lipophilic, membrane-soluble pronucleotides is described. The cycloSal moiety was introduced by using cyclic chlorophosphite agents prepared from phenyl-substituted saligenin derivatives and ortho-hydroxymethylated naphthols, respectively. Hydrolysis studies (HPLC analysis) of the triesters 2, 3 showed a range of hydrolytic stability from 1.4 h up to 5.1 h and the stability could be correlated with the substitution pattern in the cycloSal moiety. A slight decrease of their stability was observed, if phenyl-substituted derivatives were hydrolyzed in human CEM/O cell extracts. D4T and thymine, possible products of enzymatic cleavage of the pronucleotides, were not detected in the cell extracts. A further investigation of the hydrolysis process was performed by 31P-NMR spectroscopy. This technique allowed a precise monitoring of the degradation products and the exact determination of the product ratio. Finally, the newly synthesized compounds were tested concerning their antiviral activity against HIV in vitro. A strong correlation of the hydrolysis properties and the antiviral activity was found. 3-phenyl-cycloSal-d4TMP showed a threefold increase in its anti-HIV-1 activity and retained full activity in thymidine kinase (TK) deficient cells, indicative of a successful TK-bypass.
描述了核苷类似物2',3'-二脱氧-2',3'-二脱氢胸苷(d4T,Zerit)的苯基取代和苯并稠合环Sal磷酸三酯作为亲脂性、膜溶性前体核苷酸的合成。环Sal部分分别通过使用由苯基取代的水杨苷衍生物和邻羟甲基化萘酚制备的环状亚磷酸氯酯试剂引入。三酯2、3的水解研究(HPLC分析)显示水解稳定性范围为1.4小时至5.1小时,且稳定性与环Sal部分的取代模式相关。如果苯基取代的衍生物在人CEM/O细胞提取物中水解,观察到其稳定性略有下降。在细胞提取物中未检测到前体核苷酸酶促裂解的可能产物d4T和胸腺嘧啶。通过31P-NMR光谱对水解过程进行了进一步研究。该技术允许精确监测降解产物并准确确定产物比例。最后,对新合成的化合物进行了体外抗HIV病毒活性测试。发现水解性质与抗病毒活性之间有很强的相关性。3-苯基-环Sal-d4TMP的抗HIV-1活性提高了三倍,并且在胸苷激酶(TK)缺陷细胞中保留了全部活性,表明成功绕过了TK。